Pembrolizumab Clinical Trial
Official title:
Pembrolizumab for Adjuvant Treatment After R0 Resection of Thoracic ESCC Patients With Lymph Node Positive: A Single-arm, Open-label, PhaseⅡTrial
The purpose of this study is to observe and evaluate the efficacy and safety of postoperative adjuvant treatment of pembrolizumab in patients with thoracic esophageal squamous cell carcinoma (ESCC) who have not received neoadjuvant therapy before undergoing R0 resection, and have positive postoperative lymph nodes.
Status | Recruiting |
Enrollment | 82 |
Est. completion date | April 30, 2024 |
Est. primary completion date | April 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Histologically confirmed ESCC; 2. Patients have not received neoadjuvant therapy. 3. Thoracic ESCC with R0 resection and positive postoperative lymph nodes; 4. Have a performance status of 0 or 1 on the ECOG Performance Scale; 5. Age 18-70 years old, both men and women; 6. Be willing and able to provide written informed consent/assent for the trial; 7. Demonstrate adequate organ function , all screening labs should be performed within 10 days of treatment initiation; 8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; 9. Be willing to provide postoperative tissue specimens. After tumor recurrence, continue to be willing to provide tissue samples such as needle biopsy. Exclusion Criteria: 1. Neoadjuvant therapy (radiotherapy, immunotherapy, or chemotherapy) for ESCC; 2. Non-R0 resection for ESCC; 3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug; 4. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); 5. Has severe hypersensitivity and adverse events (=Grade 3) to pembrolizumab and/or any PD-1/PD-L1 inhibitors. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Medical University Cancer Institute and Hospital | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Medical University Cancer Institute and Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival (OS) | Time from the enrollment to death of any cause | 24 months | |
Primary | Disease-free survival (DFS) | Time from the enrollment to disease relapse after complete resection or death from any cause | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06389422 -
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
|
Phase 2 | |
Recruiting |
NCT06102395 -
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
|
Phase 3 | |
Recruiting |
NCT05910710 -
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
|
||
Not yet recruiting |
NCT05286320 -
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04955743 -
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT04925986 -
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT04333004 -
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04393883 -
A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)
|
N/A | |
Recruiting |
NCT04813523 -
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma
|
Phase 2 |